Bicalutamide (Casodex®) in the treatment of prostate cancer

References

• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, version 1.0, 5th edition. IARC Press, Lyon, France (2001).
   Google Scholar
• Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. j Ural 159,1431–1436 (1998).
   Google Scholar
• Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J. Med. 347, 781–789 (2002).
   PubMed Web of Science ®Google Scholar
• Campbell T, Blasko J, Crawford ED et al Clinical staging of prostate cancer: reproducibility and clarification of issues. Int.j Cancer96, 198–209 (2001).
   PubMedGoogle Scholar
• Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. j Ural 164,101–105 (2000).
   PubMedGoogle Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAIVIA 281,1591–1597 (1999).
   PubMed Web of Science ®Google Scholar
• Roach M, Lu J, Pilepich MV et al Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int. j Radiat. Oncol Biol. Phys. 47,609–615 (2000).
   PubMed Web of Science ®Google Scholar
• Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am. j Surg. Pathol 20,286–292 (1996).
   Google Scholar
• Tyrrell CJ. Adjuvant and neoadjuvant hormonal therapy for prostate cancer. Eur. Ural 36,549–558 (1999).
   PubMedGoogle Scholar
• •Comprehensive review of neoadjuvant and adjuvant hormonal therapy.
   Google Scholar
• Cassileth BR, Soloway MS, Vogelzang NJ et al Quality of life and psychosocial status in stage D prostate cancer. Qua Life Res. 1, 323–329 (1992).
   PubMedGoogle Scholar
• Cassileth BR, Soloway MS, Vogelzang NJ et al Patients' choice of the treatment in stage D prostate cancer. Urology 33\(Suppl. 5), 57–62 (1989).
   Google Scholar
• Vogelzang NJ, Chodak GW, Soloway MS et al Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 46, 220–226 (1995).
   PubMed Web of Science ®Google Scholar
• Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. BE j Uml. 67,502–508 (1991).
   Google Scholar
• Samdal F, Vada K, Lundmo PI, Mjolnerod OK. Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate? Scand Ural Nephml. 25,197–199 (1991).
   Google Scholar
• Denis L. Role of maximal androgen blockade in advanced prostate cancer. Prostate Suppl 5,17–22 (1994).
   PubMedGoogle Scholar
• Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346,265–269 (1995).
   Google Scholar
• Caubet JF, Tosteson TD, Dong EW et al Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomised controlled trials using nonsteroidal anti-androgens. Urology 49,71–78 (1997).
   PubMed Web of Science ®Google Scholar
• Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 355, 1491–1498 (2000).
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl. J. Med. 339, 1036–1042 (1998).
   PubMed Web of Science ®Google Scholar
• Small EJ, Reese DM, Vogelzang NJ. Hormone-refractory prostate cancer: an evolving standard of care. Sernin. Oncol 26\(Suppl. 17), 61–67 (1999).
   Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Phatmacol Ther. 82,241–250 (1999).
   PubMed Web of Science ®Google Scholar
• Nelson JB, Nabulsi AA, Vogelzang NJ et al Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J. Um/. 169,1143–1149 (2003).
   Google Scholar
• Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Database report on prostate carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer83, 1679–1684 (1998).
   Google Scholar
• Kirby R. Treatment options for early prostate cancer. Urology52,948–962 (1998).
   PubMed Web of Science ®Google Scholar
• Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Um/. 163, 181–186 (2000).
   Google Scholar
• Gardiner RA, Green H, Yaxley J et al Cognition and hormonal manipulation in prostate cancer. BE j Ural Int. 86\(Suppl. 3), 218–219 (2000) (Abstract MP6.1.03).
   Google Scholar
• Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am. J. Hematol 59,230–233 (1998).
   PubMed Web of Science ®Google Scholar
• Cockshott ID, Sotaniemi EA, Cooper KJ, Jones DC. The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. BE j Clin. Pharmacol 36,339–343 (1993).
   PubMed Web of Science ®Google Scholar
• Furr BJ, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Um/ogy47(Suppl. 1A), 13–25 (1996).
   Google Scholar
• Kolvenbag GJCM, Furr BJA, BlacIdedge GRP. Receptor affinity and potency of non-steroidal anti-androgens: translation of preclinical findings into clinical activity. Prost. Cancer PD1, 307–314 (1998).
   Google Scholar
• Furr BJA. Relative potencies of flutamide and `Casodex'. Endocr Relat. Cancer 4, 197–202 (1997).
   Web of Science ®Google Scholar
• Teutsch G, Goubet F, Battmann T et al Non-steroidal anti-androgens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J. Steroid. Biochem. Mal Biol. 48,111–119 (1994).
   PubMed Web of Science ®Google Scholar
• Culig Z, Hoffman NJ, Erdel M et al Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. BE J. Cancer 81, 242–251 (1999).
   Google Scholar
• Fenton MA, Shuster TD, Fertig AM et al Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 3,1383–1388 (1997).
   PubMed Web of Science ®Google Scholar
• Kemppainen JA, Wilson EM. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Urology 48, 157–163 (1996).
   PubMed Web of Science ®Google Scholar
• McLeod DG, Iversen P. Gynecomastia in patients with prostate cancer: a review of treatment options. Urology56, 713–720 (2000).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of managementoptions for gynecomastia in patients with prostate cancer.
   Google Scholar
• Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID. Casodex 10–200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three Phase III dose-ranging studies. Casodex Study Group. Eur Ural 33,39–53 (1998).
   Google Scholar
• Verhelst J, Denis L, VanVliet P et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin. Enclocrinol 41,525–530 (1994).
   PubMed Web of Science ®Google Scholar
• Cockshott ID, Oliver SD, Young JJ, Cooper KS, Jones DC. The effect of food on the pharmacokinetics of the bicalutamide (Casodex') enantiomers. Biopharm. Drug-Dispos. 18,499–507 (1997).
   Google Scholar
• Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NS, Denis L. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Ural 18\(Suppl. 3), 10–17 (1990).
   Google Scholar
• Mahler C, Verhelst J, Denis L. Clinical pharmacokinetics of the anti-androgens and their efficacy in prostate cancer. Clin. Phalmacokinet. 34,405–417 (1998).
   PubMed Web of Science ®Google Scholar
• McKillop D, Boyle GW, Cockshott ID, Jones DC, Phillips PJ, Yates RA. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 23,1241–1253 (1993).
   PubMed Web of Science ®Google Scholar
• Kaisary A, Klarskov P, McKillop D. Absence of hepatic enzyme induction in prostate cancer patients receiving `Casodex' (bicalutamide). Anti Cancer Drugs 7,54–59 (1996).
   Google Scholar
• Cockshott I. Bicalutamide: clinical pharmacokinetics and metabolism. Clin. Pharmacokinet. (2003) (In Press).
   Google Scholar
• Denis L, Mahler C. Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. Urology 47(Suppl. 1A), 26–28 (1996).
   Google Scholar
• Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47, 38–43 (1996).
   PubMed Web of Science ®Google Scholar
• Kolvenbag GJCM, Nash A. Bicalutamide dosages used in the treatment of prostate cancer. Prostate 39,47–53 (1999).
   PubMedGoogle Scholar
• Schellhammer PF, Sharifi R, Block NL et al Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology50, 330–336 (1997).
   PubMed Web of Science ®Google Scholar
• •Mature results from a randomized comparison of two nonsteroidal antiandrogens in maximum androgen blockade (MAK
   Google Scholar
• Schellhammer P, Sharifi R, Block N et al A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology45, 745–752 (1995).
   PubMed Web of Science ®Google Scholar
• Sarosdy MF, Schellhammer PF, Sharifi R et al Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology52,82–88 (1998).
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology51, 389–396 (1998).
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Kaisary AV, Iversen P et al A randomised comparison of `Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Ural 33,447–456 (1998).
   PubMed Web of Science ®Google Scholar
• ••Mature analysis of bicalutamidemonotherapy versus castration in Ml patients.
   Google Scholar
• Kaisary AV, Iversen P, Tyrrell CJ et al Is there a role for anti-androgen monotherapy in patients with metastatic prostate cancer? Prostate Cancer PD 4, 196–203 (2001).
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV et al Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up.j Ural 164,1579–1582 (2000).
   Google Scholar
• ••Mature analysis of bicalutamidemonotherapy versus castration in MO patients.
   Google Scholar
• Iversen P, Melezinek I, Schmidt A. Nonsteroidal anti-androgens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BE j Uml. Int. 87,47-56 (2001).
   Google Scholar
• ••Comprehensive review of the effects ofnonsteroidal antiandrogens on sexual interest and function.
   Google Scholar
• Boccardo F, Rubagotti A, Barichello M et al Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients. Results of an Italian Prostate Cancer Project (PONCAP) study. J. Clin. Oncol 17,2027–2038 (1999).
   Google Scholar
• •Comparison of bicalutamide monotherapy and MAB in MO and Ml patients.
   Google Scholar
• Fourcade RO, Chatelain C, Poterre M. An open multicentre randomised study to compare the effect and safety of `Casodex' (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur. Ural 33,88 (1998) (Abstract 349).
   Google Scholar
• Kucuk O, Fisher E, Moinpour CM et al Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology58,53–58 (2001).
   PubMed Web of Science ®Google Scholar
• Joyce R, Fenton MA, Rode P et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.J Ural 159,149–153 (1998).
   PubMed Web of Science ®Google Scholar
• Scher HI, Liebertz C, Kelly WK et al Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Clin. Oncol 15,2928–2938 (1997).
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351,1451–1467 (1998).
   PubMed Web of Science ®Google Scholar
• Chodak GW, Kolvenbag GJCM. Will the experience with tamoxifen in breast cancer help define the role of anti-androgens in prostate cancer? Prost. Cancer PD 4, 72–80 (2001).
   Google Scholar
• Lawton CA, Winter K, Murray K et al Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol Biol. Phys. 49,937-946 (2001).
   Google Scholar
• Hanks GE, Lu J, Machtay M et al RTOG protocol 92–02: a Phase III trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc. Am. Soc. Clin. Oncol 19,327a (2000) (Abstract 1284).
   Google Scholar
• Prayer-Galetti T, Zattoni F, Capizzi A, Dal Moro F, Pagano E Disease-free survival in patients with pathological 'C Stage' prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment. Eur. Ural 38,504 (2000) (Abstract 48).
   Google Scholar
• Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl. J. Merl 341,1781–1788 (1999).
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L et al Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 360, 103–108 (2002).
   PubMed Web of Science ®Google Scholar
• Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study.j Ural 159, 2030–2034 (1998).
   PubMedGoogle Scholar
• Pilepich MV, Caplan R, Byhardt RVV et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. j din. Oncol 15, 1013–1021 (1997).
   Google Scholar
• See WA, McLeod D, Iversen P et al The bicalutamide Early Prostate Cancer program. Demography. Ural Oncol 6, 43–47 (2001).
   PubMedGoogle Scholar
• ••Description of the design and patient demography of the bicalutamide Early Prostate Cancer (EPC) program.
   Google Scholar
• See WA, McLeod DG, Wirth MP et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. j Ural 168, 429–435 (2002).
   PubMed Web of Science ®Google Scholar
• ••Results from the first combined analysis ofthe bicalutamide EPC program demonstrating a significant benefit with bicalutamide in terms of time to progression.
   Google Scholar
• See WA. PSA changes in early prostate cancer: implications for patient management. Eur. Ural Suppl 1,17–23 (2002).
   Google Scholar
• Iversen P, Tammela TLJ, Vaage S et al A randomised comparison of bicalutamide (Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Ural 42,204–211 (2002).
   Google Scholar
• •Results from the Scandinavian arm of the bicalutamide EPC program.
   Google Scholar
• McLeod DG. Tolerability of nonsteroidal anti-androgens in the treatment of advanced prostate cancer. Oncologist 2, 18–27 (1997).
   PubMedGoogle Scholar
• •Detailed review of the side effects of the nonsteroidal antiandrogens.
   Google Scholar
• Payne H, Tyrrell C, Tammela T et al Prophylactic breast irradiation significantly reduces the incidence of bicalutamide (Casodex')-induced gynecomastia. int. j Racliat. Oncol Biol. Phys. 54,135 (2002).
   Google Scholar
• Saltzstein D, Cantwell A, Sieber P et al. Prophylactic tamoxifen significantly reduces the incidence of bicalutamide-induced gynecomastia and breast pain. Br.Ural Int. 90,120 (2002).
   Google Scholar
• Sieber PR, Keiller DL, Kahnoski RJ et al Bone mineral density is maintained during bicalutamide (Casodex') treatment. Proc. Am. Soc. Clin. Oncol 21,196a (2002).
   Google Scholar
• Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. j Ural 155, 209–212 (1996).
   PubMedGoogle Scholar
• McCaffrey JA, Scher HI. Interstitial pneumonitis following bicalutamide treatment for prostate cancer. J. Ural 160,131 (1998).
   PubMedGoogle Scholar
• Dole EJ, Holdsworth MT Nilutamide: an anti-androgen for the treatment of prostate cancer. Ann. Pharmacother. 31,65–75 (1997).
   PubMed Web of Science ®Google Scholar